Retractable Technologies heads into the week with a quiet but telling split: the stock is down 8% over five sessions while its founder-CEO has been building his stake for months at prices well above the current level.
The price story is simple and unflattering. RVP closed at $0.64 on Friday, off 7% on the day and down 5% over the past month. There is no obvious catalyst — just a low-volume micro-cap grinding lower with no options market activity and no analyst coverage to arrest the slide. The 52-week low is close.
The borrow market is almost entirely uninvolved. Short interest is a fractional 0.15% of free float — too small to matter as a directional signal. The week-on-week figure shows a 25% rise in shares short, but in absolute terms that represents a move from roughly 36,000 shares to 46,000 shares, a rounding error for any stock. Cost to borrow has drifted up modestly, now near 6.4%, but availability remains extremely loose — there is ample supply for any short seller who wants in. The ORTEX short score of 29.9 is unremarkable, and borrow conditions give no sign of squeeze pressure.
The most genuinely interesting data point is ownership. Thomas Shaw — founder, chairman, president, and CEO — holds 55.7% of the company and was an active buyer through October and November 2025, accumulating shares in a series of small purchases across prices ranging from roughly $0.77 to $0.96. Those purchases now sit underwater. His last reported transaction was in mid-November, and the insider data is now over six months old, so the pattern should be treated as historical context rather than a live signal. Still, a founder holding more than half the company and buying repeatedly at prices 20-50% above the current level is a fact worth noting.
Institutional presence is thin. Vanguard holds a 2.2% passive position, unchanged as of March 2026. Eversept Partners, a specialist healthcare fund, added 217,000 shares through December 2025 to reach a 1.9% stake. Beyond those, there are few names of note — a total holder count of just 29 institutional filers. With Shaw dominating the cap table, the free float is narrow and liquidity constrained, which explains the outsized percentage moves on what are likely modest volume days.
The earnings history adds a small wrinkle. A May 8 filing produced a 3% one-day drop and a 9% five-day decline. A separate March 27 disclosure moved the stock modestly higher on the day and held a 3.7% gain over five sessions. There is no confirmed upcoming event, but a filing appeared on May 15 — the most recent entry in the event log carries no price reaction data yet, suggesting it may be a non-earnings disclosure. That filing, combined with the week's price decline, is the immediate focus for anyone still following this name.
What to watch: whether Shaw's last-reported buying level near $0.77–$0.96 proves to be a floor in the coming sessions, and whether the May 15 filing carries any operational update that the market has yet to price.
See the live data behind this article on ORTEX.
Open RVP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
